HPTN 084 Study Demonstrates Superiority of Injectable Cabotegravir to Oral FTC/TDF for the Prevention of HIV in Cisgender Women in Sub-Saharan Africa Nov 9, 2020
CAB LA proves to be highly effective for prevention of HIV acquisition in cisgender men and transgender women May 18, 2020
